The Government of Mexico announced a 12.25-billion-peso investment by four leading pharmaceutical companies—Boehringer Ingelheim (3.5 billion), Carnot Laboratories (3.5 billion), Bayer (3 billion), and AstraZeneca (2.25 billion)—to boost production, research, and drug development nationwide. The initiative will create 3,120 highly specialized direct jobs and 22,500 indirect jobs, strengthening Mexico’s position in the global pharmaceutical sector.
During her “People’s Morning Conference,” President Claudia Sheinbaum Pardo emphasized that this investment is part of the Mexico Plan, marking a decisive step toward development with social well-being. She also announced the creation of the first Economic Development Hub for Well-being (PODECOBI), the “Parque Industrial Bajío,” in Zinapécuaro, Michoacán. This project, backed by Citelis and Artifibras, will have an initial public-private investment exceeding one billion pesos.
Secretary of Economy Marcelo Ebrard Casaubon described the pharmaceutical investment as a priority for its impact on public health, while Secretary of Health David Kershenobich Stalnikowitz highlighted that the sector is undergoing a transformative phase driven by innovation, clinical research, and process digitalization.
Company executives detailed how the investments will be allocated: Bayer will expand its capacity in plants located in Veracruz, the State of Mexico, and Tlaxcala; Boehringer Ingelheim will convert its Xochimilco facility into the world’s largest tablet production plant; Carnot will build a new plant in Hidalgo; and AstraZeneca will expand both its innovation center and plant in the State of Mexico.
Michoacán Governor Alfredo Ramírez Bedolla noted that the Parque Industrial Bajío will position the region as an international logistics hub, leveraging its strategic connections via rail, the Port of Lázaro Cárdenas, the Western Highway, and the Morelia International Airport.
